Venture capital raised by biopharma companies.
Biopharma-specific venture funding
Takeaway: The recovery is real but the capital is going to later-stage assets.
Biopharma VC
Venture capital raised by biopharma companies, $ billions.
Takeaway: The recovery is real but the capital is going to later-stage assets.
Biopharma VC
The recovery is real but the capital is going to later-stage assets.
Rendering the interactive chart…
Expand data table
| Period | Series | Value | Value basis | Source |
|---|---|---|---|---|
| 2023 | $bn raised | 23.3 | Actual | BioPharma Dive: Biotech venture capital funding tracker |
| 2024 | $bn raised | 26 | Actual | BioPharma Dive: Biotech venture capital funding tracker |
Data table
Download CSV| Year | USD b | Series | Source | Value basis |
|---|---|---|---|---|
| 2023 | 23.3 | biopharma_vc | BioPharma Dive: Biotech venture capital funding tracker | Actual |
| 2024 | 26 | biopharma_vc | BioPharma Dive: Biotech venture capital funding tracker | Actual |
How this evidence was built
What it measures
Two series with deliberately different scopes: "global biotech" is the broad sector total, "biopharma" is the narrower drug-developer subset. They are not alternative estimates of the same quantity and should not be compared point-to-point.
Key context
- Venture funding totals vary materially between data providers depending on whether crossover rounds, corporate venture and non-dilutive grants are counted.
- Each series here is kept to a single provider so the trend within a series is consistent.
Key numbers
- Biotech VC peaked near $42bn in 2021 (mckinsey-biotech-vc).
- Recovery to ~$38bn in 2025, a 28% gain on $29.7bn in 2024 (mckinsey-biotech-vc).
- Biopharma raised $23.3bn (2023) and $26bn (2024) (biopharmadive-tracker).
Caveats
Caveat: 2020, 2022 and 2023 global totals are described qualitatively in the cited sources as a "funding winter" but no figure is published, so those years are omitted rather than estimated from the narrative.
Do not use this to
- Stage or therapeutic-area breakdowns.
- Deal counts or median round sizes.
- Returns or exit outcomes.
Scope
2025
Sources
Last verified 10 Sept 2026